Show simple item record Krakowski MI Czobor, Pál 2016-01-15T07:27:22Z 2016-01-15T07:27:22Z 2012
dc.identifier 84856301116
dc.identifier.citation pagination=74-80; journalVolume=73; journalIssueNumber=1; journalTitle=JOURNAL OF CLINICAL PSYCHIATRY;
dc.identifier.uri doi:10.4088/JCP.11m07238
dc.description.abstract OBJECTIVE: Despite extensive experience with antipsychotic medications, we have limited capacity to predict which patients will benefit from which medications and for what symptoms. Such prediction is of particular importance for the proper treatment of violence. Our goal was to determine whether executive function predicts outcome of treatment for aggressive behavior and whether such prediction varies across medication groups. METHOD: Ninety-nine physically aggressive inpatients (aged 18-60 years) with schizophrenia or schizoaffective disorder (diagnosed according to DSM-IV) who completed tests of executive function were randomly assigned in a double-blind, parallel-group, 12-week trial to clozapine (n = 32), olanzapine (n = 32), or haloperidol (n = 35). The number and severity of aggressive events as measured by the Modified Overt Aggression Scale (MOAS) were the outcome measures. Psychopathology and medication side effects were also assessed. The study was conducted from 1999 to 2004. RESULTS: Poor executive function predicted higher levels of aggression, as measured by MOAS scores over the 12-week period, in all 3 medication groups (F(1,98) = 222.2, P < .0001). There was, however, a significant interaction effect between medication grouping and executive function (F(1,98) = 15.32, P < .001): clozapine exerted an antiaggression effect even in the presence of executive dysfunction. CONCLUSIONS: Executive function was a strong predictor of response to antiaggression treatment in all medication groups, but clozapine still retained clinical efficacy in the presence of poor executive functioning. Olanzapine was particularly efficacious in the absence of executive dysfunction. These findings have important implications for a targeted approach to the treatment of aggression in patients with schizophrenia. TRIAL REGISTRATION: Identifier: NCT01123408.
dc.relation.ispartof urn:issn:0160-6689
dc.title Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial.
dc.type Journal Article 2015-08-10T07:44:41Z
dc.language.rfc3066 en
dc.identifier.mtmt 1939698
dc.identifier.wos 000299408400011
dc.identifier.pubmed 22152404
dc.contributor.department SE/AOK/K/Pszichiátriai és Pszichoterápiás Klinika
dc.contributor.institution Semmelweis Egyetem

Files in this item



This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account